NUZ-001 arm in HEALEY ALS trial expands to 240 participants

An arm of the HEALEY ALS platform trial testing Neurizon Therapeutics’ experimental therapy NUZ-001 as a treatment for amyotrophic lateral sclerosis (ALS) is expanding enrollment from 160 to as many as 240 participants. The decision follows enrollment that exceeded original expectations and the absence of another HEALEY regimen…

Regulatory authorities in the Netherlands have given the green light for a clinical trial testing Ability Neurotech‘s experimental brain-implantable technology as a way to restore communication and speech in people with amyotrophic lateral sclerosis (ALS). The study is designed to assess whether the system can support independent communication…

French actor Pierre Deny, known for his role in the Netflix streaming series “Emily in Paris,” has died from amyotrophic lateral sclerosis (ALS) at age 69. “It is with deep emotion that we announce the passing of Pierre Deny, which occurred this Monday following a sudden and severe case of…

Every May for the past five years, the nonprofit I AM ALS hosts a summit to raise ALS awareness, the hallmark of which is a display of 6,000 small blue flags planted on the National Mall in Washington, D.C. Each flag represents a person who is living with…

Living in areas with a moderate amount of green space appears to reduce the likelihood of developing amyotrophic lateral sclerosis (ALS) — but both very low and very high levels of greenness may increase the odds for different reasons, according to a study from Italy. The findings “may have…

There is an association between traumatic head injuries and amyotrophic lateral sclerosis (ALS), but the nature of this relationship remains unclear, according to a review and meta-analysis of published studies. People who had a history of a traumatic head injury were nearly 50% more likely than those without head…

The longer I live with ALS, the more I’m forced to learn about myself by constantly adjusting to my body’s limitations and learning how to pace my days. Lately, I’ve been taking lessons in how to thrive from a large, graceful houseplant on our back porch. We are both,…

AC Immune’s experimental imaging agent ACI-19626 continues to show a good safety profile and has shown promise for detecting toxic TDP-43 protein clumps in people with amyotrophic lateral sclerosis (ALS). That’s according to new data from an ongoing Phase 1 clinical trial (NCT06891716), in which the PET…